Up to date, in literature, it is still debated the role of anti-
tumor necrosis factors (TNF)-α treatments in hepatitis C virus (HCV) patients. TNF-α performs a lot of functions, it is an important pro-inflammatory
cytokine and it is involved in the host's immunity. Since TNF-α is implicated in the apoptotic signaling pathway of hepatocytes infected by HCV, anti TNF-α
therapy may increase the risk of viral replication or their reactivation. However the treatment of anti TNF-α could have a healthful role because TNF-α appears to be engaged in the pathogenesis of
liver fibrosis, inducing apoptotic pathways. We describe the case of a patient with plaque-type
psoriasis and concomitant chronic HCV, who was treated successfully with anti-TNF agents simultaneously to
cyclosporine without sign of reactivation of HCV and increase of liver
enzymes. Our personal experience shows that anti-TNF-α agents are not only effective but also safe. Furthermore the combination
therapy of
cyclosporine and anti-TNF-α appears to be well-tolerated and able to reduce the amount of liver
enzymes as well as HCV-viral-load. However systematic, large-scale studies with long follow-ups will be needed to confirm our results, in association with close liver function monitoring.